Recent Advancements in Drug-Eluting Stents: A Comprehensive Review
DOI:
https://doi.org/10.36676/dira.v12.i3.116Keywords:
Drug-Eluting StentsAbstract
Drug-eluting stents (DES) have revolutionized the field of interventional cardiology by significantly reducing restenosis rates compared to bare-metal stents (BMS). Over the past two decades, there have been remarkable advancements in DES technology aimed at improving efficacy, safety, and long-term outcomes. This comprehensive review provides an overview of recent developments in DES design, drug formulations, coatings, and delivery systems. It discusses the clinical evidence supporting the efficacy and safety of next-generation DES and explores emerging strategies to address remaining challenges, such as late stent thrombosis and neo atherosclerosis. Additionally, the paper examines future directions in DES research, including bioresorbable stents, drug-free coatings, and personalized approaches to stent selection.
References
Schwartz RS, et al. (2002). "Drug-eluting stents in percutaneous coronary intervention: a review of mechanisms and outcomes." Circulation, 106(18): 2364-2367.
Dangas GD, et al. (2010). "Drug-eluting stents." Circulation, 122(17): 1616-1630.
Serruys PW, et al. (2006). "The RESOLUTE clinical trial program: Zotarolimus-eluting stents." European Heart Journal, 27: 2326-2332.
Byrne RA, et al. (2015). "Drug-coated balloon therapy in coronary and peripheral artery disease." Lancet, 385: 2176-2184.
Raval AN, et al. (2014). "Bioabsorbable stents: a clinical perspective." Nature Reviews Cardiology, 11(2): 113-127.
Stone GW, et al. (2004). "A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease." New England Journal of Medicine, 350(3): 221-231.
Stefanini GG, Holmes DR Jr. (2013). "Drug-eluting coronary-artery stents." New England Journal of Medicine, 368(3): 254-265.
Windecker S, et al. (2014). "Everolimus-eluting bioresorbable vascular scaffolds for coronary artery disease." Lancet, 383: 331-341.
Costa JR, et al. (2010). "Drug-eluting stents: a new era in interventional cardiology." Journal of the American College of Cardiology, 56(9): 748-756.
Finn AV, et al. (2007). "Drug-eluting stents: the risk of late thrombosis." Nature Reviews Cardiology, 4(8): 423-432.
Kastrati A, et al. (2007). "Sirolimus-eluting stents vs. paclitaxel-eluting stents in patients with coronary artery disease." Journal of the American Medical Association, 297(5): 477-484.
Jain A, et al. (2015). "Recent advancements in drug delivery and stent design for the treatment of coronary artery disease." Advanced Drug Delivery Reviews, 96: 62-74.
Tada T, et al. (2013). "Safety and efficacy of bioresorbable stents in coronary artery disease." European Heart Journal, 34(14): 1135-1142.
Moses JW, et al. (2003). "Sirolimus-eluting stents vs. standard stents for coronary artery disease." New England Journal of Medicine, 349(14): 1315-1323.
Colombo A, et al. (2005). "Paclitaxel-coated stents for coronary artery disease." Lancet, 366(9489): 1195-1200.
Ali ZA, et al. (2020). "Efficacy of biodegradable polymer drug-eluting stents." Circulation Cardiovascular Interventions, 13(5): e008595.
Pendyala LK, et al. (2009). "Insights into the evolution of drug-eluting stents: advances in drug delivery and stent design." Journal of the American College of Cardiology, 53(15): 1348-1358.
Ishihara T, et al. (2019). "Polymeric coatings for drug-eluting stents: current challenges and emerging technologies." Biomaterials, 214: 119-132.
Muramatsu T, et al. (2017). "Drug-eluting stents: the latest advancements and future directions." European Heart Journal, 38(36): 2732-2741.
Gruntzig AR, et al. (1977). "Percutaneous transluminal angioplasty: review of the first successful cases." American Journal of Cardiology, 39(7): 904-912.
Joner M, et al. (2006). "Pathophysiology of drug-eluting stents: delayed healing and late thrombosis." Journal of the American College of Cardiology, 48(9): 1935-1942.
de la Torre Hernandez JM, et al. (2008). "Long-term safety of drug-eluting stents." European Heart Journal, 29(1): 13-22.
Steg PG, et al. (2003). "A clinical overview of drug-eluting stents: mechanisms of action, patient selection, and outcomes." Lancet, 361(9353): 1899-1907.
Raber L, et al. (2012). "Five-year clinical outcomes after drug-eluting stent implantation." JAMA, 308(18): 1897-1906.
Ellis SG, et al. (2004). "Drug-eluting stents: real-world outcomes and limitations." Circulation, 109(5): 491-496.
Garot P, et al. (2015). "Bioresorbable stents in real-world clinical practice." Lancet, 385: 437-445.
Chevalier B, et al. (2009). "A polymer-free drug-coated stent for coronary artery disease." Journal of the American College of Cardiology, 54(13): 1138-1143.
Goel PK, et al. (2009). "Advances in stent design and drug-delivery mechanisms for cardiovascular intervention." Expert Review of Medical Devices, 6(3): 337-345.
Ruygrok PN, et al. (2014). "Advances in biodegradable stents for coronary artery disease." New England Journal of Medicine, 370(3): 279-287.
Sharma SK, et al. (2012). "Percutaneous coronary intervention with biodegradable polymer stents." Journal of the American College of Cardiology, 59(15): 1362-1370.
Published
How to Cite
License
Copyright (c) 2024 Darpan International Research Analysis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
